Evidence map›Paper›PMID 40502162›Full record

ArticlebioRxiv : the preprint server for biology2025

OGDHL regulates tumor growth, neuroendocrine marker expression, and nucleotide abundance in prostate cancer.

Matthew J Bernard, Angel Ruiz, Johnny A Diaz, Nicholas M Nunley, Rachel N Dove, Shile Zhang, Ernie Lee, Kylie Y Heering, Sachi Bopardikar, Andrea Gallardo and 15 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Matthew J BernardMolecular Biology Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0003-2417-7508
Angel RuizMolecular Biology Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Johnny A DiazMolecular Biology Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Nicholas M NunleyDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Rachel N DoveDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Shile ZhangDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Ernie LeeDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Kylie Y HeeringDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Sachi BopardikarDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Andrea GallardoDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Takao HashimotoDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Raag AgrawalDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Chad M SmithDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Blake R WildeJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0002-8372-3954
Nedas MatulionisDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0001-7624-3090
Helen M RichardsDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Sandy Che-Eun S LeePulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
Marina N SharifiCarbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53792, USA.ORCID 0000-0003-0128-3033
Joshua M LangCarbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53792, USA.ORCID 0000-0002-0943-8872
Shuang G ZhaoCarbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53792, USA.ORCID 0000-0002-9166-6507
Michael C HaffnerDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-0809-6425
David B ShackelfordJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0002-8270-898X
Paul C BoutrosDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0003-0553-7520
Heather R ChristofkJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0002-8662-4425
Andrew S GoldsteinDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0003-0434-9149

Funding

Tumor Immunology and Immunotherapy (TII)P30CA016042 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 1985 to 2025
$29.3M
UCLA Clinical and Translational Science InstituteUL1TR001881 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2025 to 2025
$9.9M
UCLA SPORE IN PROSTATE CANCERP50CA092131 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2002 to 2005
$8.7M
RESEARCH TRAINING IN CELLULAR AND MOLECULAR BIOLOGYT32GM007185 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 1985 to 2005
$5.7M
UCLA-Caltech Medical Scientist Training ProgramT32GM152342 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2024 to 2025
$3.5M
Nutrient Regulation of Cancer Cell GrowthR01CA215185 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2021 to 2025
$1.3M
Virginia-UCLA-Toronto Biomarker Characterization CenterU2CCA271894 · OLD DOMINION UNIVERSITY · 2025 to 2025
$843k
Germline Determinants of Prostate Cancer EvolutionR01CA270108 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2025 to 2025
$729k
Augmenting PSMA expression to enhance PSMA directed therapeutic efficacyR37CA286450 · FRED HUTCHINSON CANCER CENTER · 2025 to 2025
$668k
In vivo imaging of mitochondria structure and function in therapy resistant lung tumorsR01CA267721 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2025 to 2025
$620k
Biomedical Data Commons Workbench (BDCW)OT2OD030544 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Shankar Subramaniam · 2020 to 2020
$500k
Imaging mitochondrial heterogeneity in LKB1 mutant lung cancerR01CA208642 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2025 to 2025
$429k
NCATS NIH HHS UL1 TR001881NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA092131NCI NIH HHS R01 CA208642NCI NIH HHS R01 CA215185NCI NIH HHS R01 CA267721NCI NIH HHS R01 CA270108NCI NIH HHS R37 CA286450NCI NIH HHS U2C CA271894NIDDK NIH HHS TL1 DK132768NIDDK NIH HHS U2C DK119886NIDDK NIH HHS U2C DK119889NIGMS NIH HHS T32 GM007185NIGMS NIH HHS T32 GM152342NIH HHS OT2 OD030544
6 · The paper itself

Abstract

As cancer cells evade therapeutic pressure and adopt alternate lineage identities not commonly observed in the tissue of origin, they likely adopt alternate metabolic programs to support their evolving demands. Targeting these alternative metabolic programs in distinct molecular subtypes of aggressive prostate cancer may lead to new therapeutic approaches to combat treatment-resistance. We identify the poorly studied metabolic enzyme Oxoglutarate Dehydrogenase-Like (OGDHL), named for its structural similarity to the tricarboxylic acid (TCA) cycle enzyme Oxoglutarate Dehydrogenase (OGDH), as an unexpected regulator of tumor growth, treatment-induced lineage plasticity, and DNA Damage in prostate cancer. While OGDHL has been described as a tumor-suppressor in various cancers, we find that its loss impairs prostate cancer cell proliferation and tumor formation. Loss of OGDHL profoundly alters Androgen Receptor inhibition-induced plasticity, including suppressing the neuroendocrine markers DLL3 and HES6, induces accumulation of the DNA damage response marker ƔH2AX, and reduces nucleotide synthesis. Our data suggest that OGDHL has minimal impact on TCA cycle activity, and that mitochondrial localization is not required for its regulation of prostate cancer plasticity and nucleotide metabolism. Finally, we demonstrate that OGDHL expression is tightly correlated with neuroendocrine differentiation in clinical prostate cancer. These findings underscore the importance of investigating poorly characterized metabolic genes as potential regulators of distinct molecular subtypes of aggressive cancer.

Identifiers

PMID40502162
PMCPMC12154886

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.